期刊文献+

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model 被引量:4

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model
原文传递
导出
摘要 Tuberous sclerosis complex (TSC) is an autosomal dominant tumor syndrome which afflicts multiple organs and for which there is no cure, such that TSC patients may develop severe mental retardation and succumb to renal or respiratory failure. TSC derives from inacti- vating mutations of either the TSC1 or TSC2 tumor suppressor gene, and the resulting inactivation of the TSC1/TSC2 protein complex causes hyperactivation of the mammalian target of rapamyein (mTOR), leading to uncontrolled cell growth and proliferation. Recent clinical trials of targeted suppression of mTOR have yielded only modest success in TSC patients. It was proposed that abrogation of a newly identified mTOR-mediated negative feedback regulation on extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway and on the well-documented RTK-PI3K-AKT signaling cascade could limit the efficacy of mTOR inhibitors in the treatment of TSC patients. Therefore, we speculate that dual inhibition of mTOR and ERK/MAPK pathways may overcome the disadvantage of single agent therapies and boost the efficacy of mTOR targeted therapies for TSC patients. Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059. When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients. Tuberous sclerosis complex (TSC) is an autosomal dominant tumor syndrome which afflicts multiple organs and for which there is no cure, such that TSC patients may develop severe mental retardation and succumb to renal or respiratory failure. TSC derives from inacti- vating mutations of either the TSC1 or TSC2 tumor suppressor gene, and the resulting inactivation of the TSC1/TSC2 protein complex causes hyperactivation of the mammalian target of rapamyein (mTOR), leading to uncontrolled cell growth and proliferation. Recent clinical trials of targeted suppression of mTOR have yielded only modest success in TSC patients. It was proposed that abrogation of a newly identified mTOR-mediated negative feedback regulation on extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway and on the well-documented RTK-PI3K-AKT signaling cascade could limit the efficacy of mTOR inhibitors in the treatment of TSC patients. Therefore, we speculate that dual inhibition of mTOR and ERK/MAPK pathways may overcome the disadvantage of single agent therapies and boost the efficacy of mTOR targeted therapies for TSC patients. Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059. When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.
出处 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2009年第6期355-361,共7页 遗传学报(英文版)
基金 supported in part by the National Natural Science Foundation of China (No. 30788004)
关键词 TSC MTOR ERK/MAPK RAPAMYCIN PD98059 TSC mTOR ERK/MAPK rapamycin PD98059
  • 相关文献

参考文献31

  • 1Bissler, J.J., McCormack, F.X., Young, L.R., Elwing, J.M., Chuck, G., Leonard, J.M., Schmithorst, V.J., Laor, T., Brody, A.S., Bean, J., Salisbury, S., and Franz, D.N. (2008). Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl. J. Med. 358: 140-151.
  • 2Brachmann, S., Fritsch, C., Maira, S.M., and Garcia-Echeverria, C. (2009). PI3K and mTOR inhibitors--a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21: 1-5.
  • 3Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A.T., Thomas, G, Kozma, S.C., Papa, A., Nardella, C., Cantley, L.C., Baselga, J., and Pandolfi, P.P. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a Pl3K-dependent feedback loop in human cancer. J. Clin. Invest. 118: 3065-3074.
  • 4Castro, A.F., Rebhun, J.F., Clark, G.J., and Quilliam, L.A. (2003). Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278: 32493-32496.
  • 5Chan, J.A., Zhang, H., Roberts, ES., Jozwiak, S., Wieslawa, G, Lewin-Kowalik, J., Kotulska, K., and Kwiatkowski, D.J. (2004). Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC 1 or TSC2 leads to roTOR activation. J. Neuropathol. Exp. Neurol. 63: 1236-1242.
  • 6Cloughesy, T.F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Yonngkin, D., Liau, L., Martin, N., Becker, D., Bergsneider, M., Lai, A., Green, R., Oglesby, T., Koleto, M., Trent, J., Horvath, S., Mischel, P.S., Mellinghoff, I.K., and Sawyers, C.L. (2008). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-defieient glioblastoma. PLoS Med. 5: e8.
  • 7Crino, P.B. (2008). Do we have a cure for tuberous sclerosis complex? Epilepsy Curr. 8: 159-162.
  • 8Crino, P.B., Nathanson, K.L., and Henske, E.P. (2006). The tuberous sclerosis complex. N. Engl. J. Med. 355: 1345-1356.
  • 9Curatolo, P., Bombardieri, R., and Jozwiak, S. (2008). Tuberous sclerosis. Lancet 372: 657-668.
  • 10Dabora, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J., Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C., Kasprzyk-Obara, J., Domanska-Pakiela, D., and Kwiatkowski, D.J. (2001). Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68: 64-80.

同被引文献1

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部